13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001263508
Total reported value
$20.0B
$20.0B
89 檔
33.3%
The Q2 2025 SEC filing reveals that Baker Bros. Advisors LP held a total portfolio value of $20.0B, covering 89 public equity positions.
In Q2 2025, Baker Bros. Advisors LP displayed an active expansion posture, initiating 12 new positions and adding to 23 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including ONC, INCY, ACAD) accounted for 33.3% of total reported equity market value during Q2 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ONC | Beone Medicines Ltd-adr | Stock-Other | 20.66% | -2.43% | — | |
| 2 | INCY | Incyte CORP | Stock-Healthcare | 20.31% | +0.86% | +0.01% | |
| 3 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 8.98% | -0.04% | +0.04% | |
| 4 | INSM | Insmed Inc | Stock-Healthcare | 7.53% | -2.27% | +43.35% | |
| 5 | SMMT | Summit Therapeutics Inc | Stock-Other | 6.96% | -1.57% | +38.07% | |
| 6 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 5.80% | -0.67% | +0.07% | |
| 7 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 3.44% | +0.32% | — | |
| 8 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 3.34% | +5.40% | +17.99% | |
| 9 | KYMR | Kymera Therapeutics Inc | Stock-Other | 2.82% | +0.83% | +10.93% | |
| 10 | ALKS | Alkermes plc | Stock-Healthcare | 1.78% | +0.60% | +42.99% | |
| 11 | REPL | Replimune Group Inc | Stock-Other | 1.00% | +0.12% | — | |
| 12 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.98% | — | +75.92% | |
| 13 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.93% | -0.44% | +18.68% | |
| 14 | ABCL | Abcellera Biologics Inc | Stock-Other | 0.92% | +0.69% | — | |
| 15 | IMVT | Immunovant Inc | Stock-Other | 0.85% | +0.27% | — | |
| 16 | GRAL | Grail Inc | Stock-Healthcare | 0.81% | +0.18% | — | |
| 17 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.76% | +0.13% | +0.23% | |
| 18 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.73% | -0.06% | — | |
| 19 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.71% | -0.13% | EXIT | |
| 20 | CELC | Celcuity Inc | Stock-Other | 0.71% | -1.04% | +28.01% | |
| 21 | KOD | Kodiak Sciences Inc | Stock-Other | 0.63% | -0.47% | — | |
| 22 | ✓ | Immatics NV | Stock-Other | 0.53% | -0.14% | +39.76% | |
| 23 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.51% | -0.07% | — | |
| 24 | DNLI | Denali Therapeutics Inc | Stock-Other | 0.51% | +0.07% | — | |
| 25 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.50% | -0.01% | +593.86% | |
| 26 | IDYA | Ideaya Biosciences Inc | Stock-Other | 0.43% | +0.18% | +99.48% | |
| 27 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.43% | +0.16% | — | |
| 28 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.41% | +0.07% | — | |
| 29 | BNTX | Biontech Se-adr | Stock-Other | 0.38% | — | +719.26% | |
| 30 | TRDA | Entrada Therapeutics Inc | Stock-Other | 0.32% | -0.18% | — | |
| 31 | ✓ | Merus N V | Stock-Other | 0.29% | — | +156.99% | |
| 32 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.28% | -0.30% | +107.97% | |
| 33 | NTLA | Intellia Therapeutics Inc | Stock-Other | 0.24% | +0.08% | NEW | |
| 34 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.24% | — | — | |
| 35 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.22% | +0.12% | — | |
| 36 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 0.21% | — | — | |
| 37 | PCVX | Vaxcyte Inc | Stock-Other | 0.20% | — | — | |
| 38 | ARGX | Argenx Se - Adr | Stock-Healthcare | 0.20% | -0.11% | EXIT | |
| 39 | ✓ | Verve Therapeutics Inc | Stock-Other | 0.18% | — | — | |
| 40 | CERS | Cerus CORP | Stock-Other | 0.18% | -0.01% | -33.42% | |
| 41 | IRON | Disc Medicine Inc | Stock-Other | 0.17% | — | +337.44% | |
| 42 | AKRO | Akero Therapeutics Inc | Stock-Other | 0.17% | — | -40.84% | |
| 43 | 2655787D | Blueprint Medicines CORP | Stock-Other | 0.16% | — | — | |
| 44 | SERA | Sera Prognostics Inc-a | Stock-Other | 0.15% | -0.01% | — | |
| 45 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 0.14% | +0.09% | — | |
| 46 | NGNE | Neurogene Inc | Stock-Other | 0.14% | +0.05% | -33.27% | |
| 47 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.14% | +0.01% | — | |
| 48 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.13% | +0.10% | +168.68% | |
| 49 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 0.13% | -0.06% | — | |
| 50 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.11% | -0.01% | +6.56% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | +3% | +43.35% | Add |
| 2 | SMMT | Summit Therapeutics Inc | +1.8% | +38.07% | Add |
| 3 | ACAD | Acadia Pharmaceuticals Inc | +1.1% | +0.04% | Add |
| 4 | KYMR | Kymera Therapeutics Inc | +1% | +10.93% | Add |
| 5 | GPCR | Structure Therapeutics Inc | +0.4% | +593.86% | Add |
| 6 | RARE | Ultragenyx Pharmaceutical In | +0.4% | +75.92% | Add |
| 7 | GRAL | Grail Inc | +0.4% | — | Unchanged |
| 8 | BNTX | Biontech Se-adr | +0.3% | +719.26% | Add |
| 9 | ABCL | Abcellera Biologics Inc | +0.2% | — | Unchanged |
| 10 | IDYA | Ideaya Biosciences Inc | +0.2% | +99.48% | Add |
| 11 | VRDN | Viridian Therapeutics Inc | +0.2% | NEW | New buy |
| 12 | RVMD | Revolution Medicines Inc | +0.2% | +17.99% | Add |
| 13 | CELC | Celcuity Inc | +0.2% | +28.01% | Add |
| 14 | ✓ | Merus N V | +0.2% | +156.99% | Add |
| 15 | NTLA | Intellia Therapeutics Inc | +0.2% | +315.40% | Add |
| 16 | ✓ | Immatics NV | +0.2% | +39.76% | Add |
| 17 | STOK | Stoke Therapeutics Inc | +0.2% | — | Unchanged |
| 18 | 2655787D | Blueprint Medicines CORP | +0.2% | NEW | New buy |
| 19 | RYTM | Rhythm Pharmaceuticals Inc | +0.2% | — | Unchanged |
| 20 | ALKS | Alkermes plc | +0.1% | +42.99% | Add |
| 21 | PRAX | Praxis Precision Medicines I | +0.1% | +107.97% | Add |
| 22 | ARWR | Arrowhead Pharmaceuticals In | +0.1% | NEW | New buy |
| 23 | DNTH | Dianthus Therapeutics Inc | +0.1% | NEW | New buy |
| 24 | IRON | Disc Medicine Inc | +0.1% | +337.44% | Add |
| 25 | CDTX | Cidara Therapeutics Inc | +0.1% | NEW | New buy |
| 26 | ACLXGBX | Arcellx Inc | +0.1% | NEW | New buy |
| 27 | NUVL | Nuvalent Inc-a | +0.1% | NEW | New buy |
| 28 | KOD | Kodiak Sciences Inc | +0.1% | — | Unchanged |
| 29 | ✓ | Verve Therapeutics Inc | +0.1% | — | Unchanged |
| 30 | SYRE | Spyre Therapeutics Inc | +0.1% | NEW | New buy |
| 31 | CLDX | Celldex Therapeutics Inc | +0.1% | +168.68% | Add |
| 32 | CRNX | Crinetics Pharmaceuticals In | +0.1% | NEW | New buy |
| 33 | CTMX | Cytomx Therapeutics Inc | +0.1% | NEW | New buy |
| 34 | KNSA | Kiniksa Pharmaceuticals International, plc | +0.1% | +0.23% | Add |
| 35 | AGIO | Agios Pharmaceuticals Inc | +0.1% | NEW | New buy |
| 36 | RAPP | Rapport Therapeutics Inc | +0.1% | NEW | New buy |
| 37 | VRNA | Verona Pharma PLC - Adr | +0.1% | — | Unchanged |
| 38 | SGMT | Sagimet Biosciences Inc-a | 0% | — | Unchanged |
| 39 | SKYE | Skye Bioscience Inc | 0% | — | Unchanged |
| 40 | TSHA | Taysha Gene Therapies Inc | 0% | — | Unchanged |
| 41 | DBVT | Dbv Technologies Sa-spon Adr | 0% | — | Unchanged |
| 42 | SION | Sionna Therapeutics Inc | 0% | — | Unchanged |
| 43 | SANA | Sana Biotechnology Inc | 0% | — | Unchanged |
| 44 | RLAY | Relay Therapeutics Inc | 0% | — | Unchanged |
| 45 | NMRA | Neumora Therapeutics Inc | — | — | Unchanged |
| 46 | TECX | Tectonic Therapeutic Inc | — | — | Unchanged |
| 47 | FATE | Fate Therapeutics Inc | — | -23.74% | Trim |
| 48 | TCRX | Tscan Therapeutics Inc | — | — | Unchanged |
| 49 | GBIOGBX | Generation Bio Co | — | — | Unchanged |
| 50 | ✓ | — | — | Unchanged |
According to official SEC Form 13F filings, Baker Bros. Advisors LP reported a total U.S. public equity portfolio value of $20.0B across 89 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
VRDN
市值: $24.4M
Top Position Liquidated / Trimmed
INSM 0.75 06-01-28
前期市值: $101.6M
During Q2 2025, Baker Bros. Advisors LP's top holdings by market value included ONC (20.7%)、INCY (20.3%)、ACAD (9.0%). The largest single position, ONC, represented 20.7% of total portfolio value.
In Q2 2025, Baker Bros. Advisors LP made 55 total portfolio adjustments, initiating 12 new buys, adding to 23 positions, trimming 8 holdings, and fully liquidating 12 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.